KR — 전자신문
ITIS and NTL Healthcare Team Up to Pursue AI-Based Women's Cancer Diagnostics Market
AI1 min read
ITIS and NTL Healthcare signed a deal to build AI tools for women's cancer testing together. They also plan to sell these tools in other countries.
What happened
ITIS, a medical AI company, signed a memorandum of understanding (MOU, a basic agreement to work together) with NTL Healthcare. The two companies will develop an AI-based women's cancer test and expand it to overseas markets. ITIS combines its medical AI platform with NTL Healthcare's skill in cervical cancer testing.
Key facts
- NTL Healthcare has worked on cervical cancer screening for about 30 years.
- Its AI cervical cancer tool, CerviCARE AI, is sold in more than 20 countries.
- NTL Healthcare plans to expand to more than 50 countries.
- ITIS's AI platform is called GENAI ME.
What is the background?
A medical AI platform is software that uses artificial intelligence to organize and study health data. Cervical cancer is cancer of the lower part of the womb, and it can be found early through screening tests. AI can help doctors read these tests more quickly and consistently.
Why it matters
This deal shows how AI could be used to find women's cancers earlier. If the tools work well in real hospitals, they could help many patients around the world. The companies say they will test the solutions and look for real business results.
What to watch
- Whether the two companies release a joint AI women's cancer test.
- How the tests perform in real clinical trials.
- Whether NTL Healthcare reaches its goal of more than 50 countries.
- Which overseas partners and markets ITIS enters.
Glossary
- GENAI ME
- ITIS's medical AI platform for combining and analyzing health data.
- CerviCARE AI
- An AI tool that helps detect cervical cancer, sold in over 20 countries.
- MOU
- A memorandum of understanding, a basic agreement to cooperate before a full contract.